Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction patient consent issues

This article was originally published in The Gray Sheet

Executive Summary

Clinical research stakeholders say a Dec. 29 proposed rule, requiring study sponsors to inform trial participants that information from the study may be submitted to the National Institutes of Health's database, should be rewritten to make the required informed consent language more readable. Commenters, including Kaiser Permanente, Johns Hopkins School of Medicine and the Association of Clinical Research Organizations, say the proposed language is far too technical. Several recommend giving sponsors leeway to craft their own patient consent language (1"The Gray Sheet" Jan. 4, 2010)

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts